Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 10/20 | 0.73 |
| ▸ | RAB9A | P51151 | 10/20 | 0.73 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.69 |
| ▸ | HPGD | P15428 | 2/20 | 0.69 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.69 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.69 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.66 |
| ▸ | MEN1 | O00255 | 2/20 | 0.66 |
| ▸ | PKM | P14618 | 1/20 | 0.65 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.62 |
| ▸ | LMNA | P02545 | 2/20 | 0.62 |
| ▸ | HTT | P42858 | 1/20 | 0.62 |
| ▸ | GFER | P55789 | 1/20 | 0.60 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8396558 | 1.00 | NPC1 (0.73) | NPC1RAB9ASMN1; SMN2HPGDCYP1A2 | |
| SCHEMBL307051 | 1.00 | NPC1 (0.73) | NPC1RAB9ASMN1; SMN2HPGDCYP1A2 | |
| SCHEMBL23594174 | 1.00 | NPC1 (0.73) | NPC1RAB9ASMN1; SMN2HPGDCYP1A2 | |
| SCHEMBL5168314 | 1.00 | NPC1 (0.73) | NPC1RAB9ASMN1; SMN2HPGDCYP1A2 | |
| Hydrochloric Acid SCHEMBL3747209 | 0.98 | NPC1 (0.71) | NPC1RAB9ASMN1; SMN2HPGDCYP1A2 | |
| Hydrochloric Acid SCHEMBL6928283 | 0.98 | NPC1 (0.71) | NPC1RAB9ASMN1; SMN2HPGDCYP1A2 | |
| SCHEMBL161227 | 0.98 | NPC1 (0.72) | NPC1RAB9ASMN1; SMN2HPGDCYP1A2 | |
| SCHEMBL2316588 | 0.94 | NPC1 (0.68) | NPC1RAB9ASMN1; SMN2HPGDCYP1A2 | |
| SCHEMBL4042448 | 0.93 | NPC1 (0.66) | NPC1RAB9ASMN1; SMN2HPGDCYP1A2 | |
| SCHEMBL23861306 | 0.92 | NPC1 (0.63) | NPC1RAB9ASMN1; SMN2HPGDCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220340570-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2022-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220340570-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | NPC1 3159/4885RAB9A 4270/4885SMN1; SMN2 2647/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.